Trials / Active Not Recruiting
Active Not RecruitingNCT06513507
A Clinical Study to Assess the Efficacy of Cannabigerol in Patients with Active Rheumatoid Arthritis.
- Status
- Active Not Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Raphael Pharma · Industry
- Sex
- All
- Age
- 25 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-group exploratory longitudinal prospective study lasting 8 weeks. The study aims to measure the efficacy of purified cannabigerol (CBG) in patients with active rheumatoid arthritis using laboratory and self-reported outcome measures.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Cannabigerol (CBG) | The daily dose will consist of 50 mg of CBG. Blood tests will be conducted at Baseline, Week 2, Week 4, Week 6, and Week 8 to monitor inflammatory markers and immune response. Self-reported questionnaires will be completed at Baseline, Week 4, and Week 8 to assess symptoms and quality of life. |
Timeline
- Start date
- 2024-06-03
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
- First posted
- 2024-07-22
- Last updated
- 2024-11-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06513507. Inclusion in this directory is not an endorsement.